NCT00826046No Longer Available不适用
Expanded Access of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 试验地点
- 3
研究概览
简要总结
This protocol allows for the treatment of patients, male and female, between the ages of 18 years and 70 years. Patients must have failed to respond to steroid treatment for Grade C-D acute GVHD.
详细描述
This is a treatment protocol to provide patients who have failed steroid treatment for acute GVHD expanded access of Prochymal. It is anticipated that a maximum of 10 patients per month for a total of 120 patients per year will be treated according to this protocol.
Patients will be treated with Prochymal twice per week at a dose of 2 x 106 human mesenchymal stem cell (hMSC)/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be 18 years to 70 years of age, inclusive.
- •Biopsy confirmation of GVHD is strongly recommended, to exclude patients presenting with diarrhea or abnormal liver function tests caused by infection.
- •Patients must have failed to respond to steroid treatment (methylprednisolone [≥1mg/kg/day] or equivalent) for Grades C-D acute GVHD.
- •Prochymal must be administered not longer than 14 days after the initiation of systemic steroid therapy for acute GVHD.
- •Prochymal must be administered either before or at the same time any additional GVHD therapy is administered
- •Patients must have an adequate renal function as defined by Cockcroft-Gault equation:Calculated creatinine clearance (CrCl) > 30 mL/min
- •Patients who are women of childbearing potential, must be non-pregnant, not breast-feeding, and use adequate contraception. Male patients must use adequate contraception.
排除标准
- •Patient has stage 3 or 4 liver GVHD, bilirubin >6 mg/dl.
- •Patient has stage 4 GI-GVHD.
- •Patient has any underlying or current medical condition that would interfere with the evaluation of the patient including uncontrolled infection, sepsis, organ failure, etc or any medical condition that has a high probability of causing death in less than 30 days.
- •Patient may not receive any other investigational agent (not approved by the FDA for any indication) concurrently for the duration of the protocol.
- •Patient has evidence of a pulmonary infiltrate or diffuse alveolar hemorrhage and must not be likely to require more than 2 liters of oxygen via face mask or an estimated fractional inspired oxygen concentration (FiO2) of 28% via other delivery methods in order to sustain an O2 saturation of 92% during the next 3 days.
- •Patient has a known allergy to bovine or porcine products
- •Patient has a medical history of a solid tumor disease.
研究者
研究点 (3)
Loading locations...
相似试验
No Longer Available
不适用
Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHDGraft vs Host DiseaseGraft-Versus-Host DiseaseNCT00759018Mesoblast, Inc.
已完成
1 期
MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLCCarcinomaNon-Small Cell Lung CancerNCT02592577Adaptimmune28
撤回
早期 1 期
Picato for the Treatment of Molluscum Contagiosum in Immunocompromised PatientsMolluscum ContagiosumNCT03336372Center for Clinical Studies, Texas
已完成
1 期
AFPᶜ³³²T in Advanced HCCHepatocellular CancerAFP Expressing TumorsNCT03132792Adaptimmune39
No Longer Available
不适用
18F-Floretyrosine Expanded Access ProgramGlioma (Any Grade) in the BrainNCT06743100Telix Pharmaceuticals (Innovations) Pty Limited